By Trana Hussaini Pharm D and Eric M. Yoshida MD FRCPC on November 13, 2019
For the first time, since the identification of hepatitis C virus, the goal of HCV elimination is a tangible and achievable target mainly due to the availability of highly efficacious and well tolerated DAA regimens.
By Dr. Eric Yoshida on July 18, 2011
This year, based on the phase III studies published in the New England Journal of Medicine, the FDA approved the new protease inhibitors, telapravir and boceprevir in combination with pegIFN and ribavirin for patients with HCV G1 infections.
Recent Comments